High risk pregnancy due to recurrent pregnancy loss

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15